The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder

作者：Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, IRETA Team · 发表于：Journal of Addiction Medicine · 年份：2024 · DOI：10.1097/adm.0000000000001299 · 被引用次数：75 · 研究领域：Attention Deficit Hyperactivity Disorder、Treatment of Major Depression、Neuroethics, Human Enhancement, Biomedical Innovations

Clinical Guideline Committee (CGC) Members: Steven Batki, MD Daniel Ciccarone, MD, MPH Scott Hadland, MD, MPH Brian Hurley, MD (Co-Chair) Kimberly Kabernagel, DO Frances Levin, MD James McKay, PhD Larissa Mooney, MD (Co-Chair) Siddarth Puri, MD Andrew Saxon, MD Kevin Sevarino, MD, PhD Kevin Simon, MD, MPH Timothy Wiegand, MD ASAM Team: Maureen Boyle, PhD Amanda Devoto, PhD Sarah Framnes-DeBoer Taleen Safarian AAAP Team: Kathryn Cates-Wessel Michelle Dirst IRETA Team: Dawn Lindsay, PhD Piper Lincoln, MS Jillian Helmick Peter Luongo, PhD Funding: The development of this guideline was generously funded with contract support from the Centers for Disease Control and Prevention (CDC) and the National Institute on Drug Abuse (NIDA). ASAM and AAAP are honored that this clinical practice guideline has been endorsed by: American College of Medical Toxicology (ACMT) American Society for Adolescent Psychiatry (ASAP) American Society of Addiction Nursing (ASAN) Abstract: The American Society of Addiction Medicine/American Academy of Addiction Psychiatry (ASAM/AAAP) Clinical Practice Guideline on the Management of Stimulant Use Disorder provides guidance on evidence-based strategies for the treatment of stimulant use disorders (StUDs), stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use. The Clinical Guideline Committee (CGC) comprised experts from ASAM and AAAP representing a range of clinical settings and p...